Personalizing EmerGency/Acute therapeuticS Utilizing Systems biology (PEGASUS)
利用系统生物学 (PEGASUS) 个性化紧急/急性治疗
基本信息
- 批准号:9690371
- 负责人:
- 金额:$ 2.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAdverse drug eventAnaphylaxisAwardCYP2D6 geneCardiovascular DiseasesCaringClinicalColoradoDataEffectivenessElectronic Health RecordEmergency SituationEnzymesFundingFutureGenetic PolymorphismGenomicsHealth Care CostsLinkModelingNauseaPainPathway interactionsPatientsPharmaceutical PreparationsPharmacogenomicsPharmacotherapyResearchResearch PersonnelSafetySystems BiologyTherapeuticTorsades de Pointesbiobankgenetic variantimprovedindividual patientmetabolomicspatient variabilitypersonalized medicinephenotypic dataprecision medicineprogramsprospective testpublic health relevancesuccess
项目摘要
Abstract
The global objective of the Personalizing EmerGency/Acute therapeuticS Utilizing Systems biology
(PEGASUS) Research Program is to improve drug effectiveness and safety in common acute care conditions.
Drug therapy for acute conditions in the emergency department is only effective in 25-60% of cases. There is
tremendous opportunity to improve acute therapeutics by implementing precision medicine programs in acute
care settings. We will use phenotypic data from our electronic health record and link this data to
pharmacogenomic and metabolomic data to discover new mechanisms of drug effectiveness and safety.
Ultimately clinical, genomic, and metabolomic data will be integrated into predictive systems biology models to
improve therapeutic success in acutely ill patients. The PEGASUS program is supported by the Rocky
Mountain Biorepository and the Colorado Center for Personalized Medicine. Through the Maximizing
Investigators' Research Award for Early Stage Investigators (MIRA-ESI) funding announcement PEGASUS will
focus on common acute care conditions such as nausea, pain, and cardiovascular disease with eventual
expansion to more uncommon drug safety conditions such as anaphylaxis and torsades de pointes. We utilize
polymorphism in drug metabolizing enzymes, such as CYP2D6, as the hub of our models and use the biologic
perturbations present in acute illness to identify new pathways, mechanisms, and genetic variants associated
with drug safety and effectiveness in these common conditions. In the future, these models will be tested
prospectively. Implementation of this systems biology approach to precision medicine will improve drug
effectiveness and safety in acute conditions.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Albert Monte其他文献
Andrew Albert Monte的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Albert Monte', 18)}}的其他基金
A FUNCTIONAL CELL BASED ASSAY FOR SYNTHETIC CANNABINOIDS
基于功能细胞的合成大麻素测定
- 批准号:
9979149 - 财政年份:2020
- 资助金额:
$ 2.52万 - 项目类别:
A FUNCTIONAL CELL BASED ASSAY FOR SYNTHETIC CANNABINOIDS
基于功能细胞的合成大麻素测定
- 批准号:
10261416 - 财政年份:2020
- 资助金额:
$ 2.52万 - 项目类别:
Personalizing EmerGency/Acute therapeuticS Utilizing Systems biology (PEGASUS)
利用系统生物学 (PEGASUS) 个性化紧急/急性治疗
- 批准号:
10242868 - 财政年份:2017
- 资助金额:
$ 2.52万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 2.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 2.52万 - 项目类别:
Operating Grants